▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China
Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China
This Q&A explores the growing gap between global pharma strategies and China’s payer priorities—offering a self-assessment tool for internal alignment, and insights into risks and opportunities in the commercial catalog pathway.
Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines
Gain practical tools and insight to navigate China’s C-List and Commercial Catalog—and make informed decisions on product positioning across emerging access pathways.
